FPF
DMK

FNY Partners Fund’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

FNY Partners Fund’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-71
Closed -$26K – 642
2017
Q3 		$26K Hold
71
– – ﹤0.01% 354
2017
Q2 		$26K Buy
+71
New +$21.3K 0.01% 325

Other funds holding DMK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BRF
B. Riley Financial Los Angeles, California $434M AUM 751.56% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $451M AUM 66.6% 1-Year Est. Return
LCM
Leisure Capital Management Costa Mesa, California $320M AUM 39.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

FNY Partners Fund's DMK Position: Q4 2017 in Review

FNY Partners Fund sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q4 2017, closing a stake of 71 shares — an estimated $26K sold.

FNY Partners Fund first reported a position in DMK in Q2 2017 and held it in 2 quarters. The position peaked at $26K in Q3 2017. 58 funds tracked by Wall St. Rank hold DMK as of Q4 2017.

  • FNY Partners Fund reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q4 2017 after selling out during the quarter.
  • FNY Partners Fund sold 71 DMK Pharmaceuticals Corporation Common Stock shares in Q4 2017, an estimated $26K.
  • FNY Partners Fund first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q2 2017 and held it in 2 quarters.
  • FNY Partners Fund's DMK Pharmaceuticals Corporation Common Stock position peaked at $26K in Q3 2017.
  • 58 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q4 2017.

Based on FNY Partners Fund's 13F filing for Q4 2017, filed 24 Jan 2018.